Evidence map›Paper›PMID 36246433›Full record

ArticleThe Canadian journal of hospital pharmacy2022

Trends in Use of Combination Antiretroviral Therapy and Treatment Response from 2000 to 2016 in the Canadian Observational Cohort (CANOC): A Longitudinal Cohort Study.

Alison R McClean, Jason Trigg, Claudette Cardinal, Mona Loutfy, Curtis Cooper, Abigail Kroch, Mostafa Shokoohi, Nimâ Machouf, Réjean Thomas, Marina B Klein and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Canadian journal of hospital pharmacy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Alison R McClean, PharmD, is with the British Columbia Centre for Excellence in HIV/AIDS and The University of British Columbia, Vancouver, British Columbia.
Jason Trigg, MA, is with the British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia.
Claudette Cardinalis with the British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia.
Mona Loutfy, MD, MPH, is with the Maple Leaf Medical Clinic, the Women's College Research Institute, and the University of Toronto, Toronto, Ontario.
Curtis Cooper, MD, MSc, is with the Ottawa Hospital Research Institute and the University of Ottawa, Ottawa, Ontario.
Abigail Kroch, MPH, PhD, is with the University of Toronto, Toronto, Ontario.
Mostafa Shokoohi, PhD, is with the University of Toronto, Toronto, Ontario.
Nimâ Machouf, PhD, is with the Clinique de Médecine Urbaine du Quartier Latin, Montréal, Quebec.
Réjean Thomas, MD, was, at the time this study was performed, with the Clinique de Médecine Urbaine du Quartier Latin, Montréal, Quebec. He is now with the Clinique médicale l'Actuel, Montréal, Quebec.
Marina B Klein, MD, MSc, is with the McGill University Health Centre, Montréal, Quebec.
Deborah V Kelly, PharmD, is with Memorial University of Newfoundland, St John's, Newfoundland and Labrador.
Alexander Wong, MD, is with the University of Saskatchewan, Regina, Saskatchewan.
Stephen Sanche, MD, is with the University of Saskatchewan, Regina, Saskatchewan.
Julio S G Montaner, MD, is with the British Columbia Centre for Excellence in HIV/AIDS and The University of British Columbia, Vancouver, British Columbia.
Robert S Hogg, PhD, is with the British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, and Simon Fraser University, Burnaby, British Columbia.
AIDS Vancouver · CAUniversity of British Columbia · CAUniversity of Saskatchewan · CAUniversity of Toronto · CAMaple Leaf Medical Clinic · CAMcGill University Health Centre · CAMemorial University of Newfoundland · CAOttawa Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Advances in treatment have turned HIV from a terminal illness to a more manageable condition. Over the past 20 years, there have been considerable changes to HIV treatment guidelines, including changes in preferred antiretrovirals and timing of initiation of combination antiretroviral therapy (cART). Objective: To examine real-world trends in cART utilization, viral control, and immune reconstitution among people living with HIV in Canada. Methods: Data were obtained from the Canadian Observational Cohort (CANOC). CANOC participants were eligible if they were antiretroviral therapy-naive at entry and initiated 3 or more antiretrovirals on or after January 1, 2000; if they were at least 18 years of age at treatment initiation; if they were residing in Canada; and if they had at least 1 viral load determination and CD4 count within 1 year of CANOC entry. Baseline and annual mean CD4 counts were categorized as less than 200, 200-350, 351-500, and more than 500 cells/mm Results: All CANOC participants were included ( Conclusions: Concordance with treatment guidelines was demonstrated over time with respect to cART prescribing and immunologic and virologic response.

Indexed as

antiretroviral therapy utilizationCD4 countHIV

Identifiers

PMID36246433
PMCPMC9524546
OpenAlexW4301182908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.